Morocco vs Ukraine: Average cost of multi drug-resistant tuberculosis treatment
Morocco
2,000 constant 2022 US$
in 2024
Ukraine
1,994 constant 2022 US$
in 2024
Morocco rank
22nd
Ukraine rank
24th
Average cost of multi drug-resistant tuberculosis treatment over time
- Morocco
- Ukraine
How they compare
Morocco currently reports 2,000 constant 2022 US$ against 1,994 constant 2022 US$ in Ukraine, a difference of 6 constant 2022 US$.
The two have swapped places 3 times across 8 shared years of data; in 2017 it was Ukraine ahead.
Morocco ranks 22nd and Ukraine ranks 24th of 92 countries.
Across the 2 decades both report, Morocco averaged higher in 1 and Ukraine in 1.
Head to head by decade
| Decade | Morocco | Ukraine | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2,127 constant 2022 US$ | 1,731 constant 2022 US$ | 395.33 constant 2022 US$ | Morocco |
| 2020s | 1,644 constant 2022 US$ | 2,144 constant 2022 US$ | 500.2 constant 2022 US$ | Ukraine |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Morocco or Ukraine?
- Morocco, at 2,000 constant 2022 US$ against 1,994 constant 2022 US$ in Ukraine as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Morocco and Ukraine?
- 6 constant 2022 US$, with Morocco ahead.
- How many years of comparable data are there for Morocco and Ukraine?
- 8 years are reported by both, from 2017 to 2024.
- How do Morocco and Ukraine rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Morocco ranks 22nd and Ukraine ranks 24th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.